Sun Pharmaceutical Industries Ltd has extended its winning streak to five consecutive sessions, trading at ₹1,914.2 with a 0.07% increase as of 12:44 IST on the NSE. According to latest reports from Business Standard, the stock has demonstrated remarkable resilience, rising 7.01% in the last one month and significantly outperforming broader market indices.
The pharmaceutical company's performance continues to stand in stark contrast to broader market indices, with Sun Pharma up 14.45% in the last one year compared to a 4.11% fall in NIFTY and a 16.43% decline in the Nifty Pharma index. As reported by Business Standard, this outperformance reflects the stock's resilience despite challenging market conditions for the pharmaceutical sector, with the company maintaining its strong momentum across multiple timeframes.
The Nifty Pharma index, of which Sun Pharmaceutical Industries Ltd is a constituent, has risen 6.88% in the last one month and is currently trading at 25,866.25, down 0.22% on the day. According to Business Standard, the benchmark NIFTY is up around 0.17% on the day, quoting at 24,472.4, while the Sensex stands at 78,420.16, up 0.17%. The pharmaceutical sector's performance continues to outpace the broader market indices despite some recent volatility.
Trading volume for the stock stood at 10.77 lakh shares today, compared to the daily average of 19.54 lakh shares in the last one month, as reported by Business Standard. The benchmark July futures contract for the stock is quoting at ₹1,917.1, down 0.05% on the day, indicating mixed sentiment in the derivatives market. The reduced trading volume compared to the monthly average suggests selective investor participation during this extended rally.
The stock's PE ratio stands at 152.92 based on TTM earnings ending March 26, according to Business Standard data. This high valuation multiple reflects the market's premium placement of Sun Pharmaceutical Industries Ltd within the pharmaceutical sector, despite the challenging overall market conditions for the industry. The PE ratio has increased from the previously reported 149.6, indicating continued premium valuation in the stock.
